Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Medical System Holdings ( (HK:0867) ) has shared an announcement.
China Medical System reported a 9.9% rise in turnover to RMB8.21 billion and an 8.3% increase in gross profit for 2025, though headline profit fell 10.5% due to a one-off tax-related payment, leaving normalized profit up 3.6%. The board proposed a higher total dividend per share, supported by a solid cash position, even as basic earnings per share declined.
The group marked 2025 as a pivotal year in its strategic transformation, with innovative and exclusive products driving nearly 60% of revenue and sales in that segment jumping 44.1%. R&D momentum accelerated with two new drugs approved and multiple NDAs and INDs in progress, while its Dermavon unit moves toward a separate Hong Kong listing and the firm deepens its international footprint via a secondary Singapore listing and an emerging markets growth platform.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings is a China-focused pharmaceutical company specializing in innovative and exclusive prescription medicines, with a growing presence in dermatology, ophthalmology and chronic disease treatments. Listed in Hong Kong and Singapore, it is pursuing a specialty-driven strategy and expanding internationally with Singapore as a hub for R&D, manufacturing and commercialization.
YTD Price Performance: -1.47%
Average Trading Volume: 3,920,495
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.01B
Find detailed analytics on 0867 stock on TipRanks’ Stock Analysis page.